Health experts question efficacy results of U.S. AstraZeneca trial

Health officials from the Data and Safety Monitoring Board, DSMB, expressed concern that the U.S. trial of the AstraZeneca vaccine may have used out of date information which gave an "incomplete view" of the efficacy. It was previously reported that the vaccine provided 79 percent efficacy against Covid-19.